Fluoxetine-induced hepatitis: why is postmarketing surveillance needed?

Entecavir treatment for chronic hepatiti

Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

✍ Roeland Zoutendijk; Jurriën G. P. Reijnders; Ashley Brown; Fabien Zoulim; David 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 1 views

Entecavir (ETV) is a potent inhibitor of viral replication in nucleos(t)ide analogue (NA)-naïve chronic hepatitis B (CHB) patients. The aim of this study was to investigate the long term efficacy and safety of ETV in NA-naïve CHB patients, particularly in those with detectable hepatitis B virus (HBV